Sterling Bay has signed four new biotech tenants at 2430 N. Halsted, a recently revamped scientific research facility in Chicago’s Lincoln Park. Seq Biomarque, a research and diagnostic technologies firm, works to develop highly sensitive blood-based multi-factor screening and diagnostic tests for Alzheimer’s disease. CeGaT Corporation is making its debut in the U.S., and the company focuses on advancements in genomics and personalized medicine.

Spun out of the University of Michigan’s on-campus lab, EVOQ Therapeutics works to reform autoimmune disease treatment with novel immunotherapies. Cyclopure specializes in water purification and water treatment technologies and is relocating to the hub from the Illinois Science + Technology Park.

Dave Gloor and Daniella Hemsley negotiated the transactions on behalf of Sterling Bay. Jonathan Metzl and Jack Deroche of Cushman & Wakefield represented Cyclopure. Sterling Bay’s life sciences hub creates adaptable lab spaces for biotech firms at different growth stages, and the property’s flexible options support startups’ evolving needs as they scale.

 “It’s about creating a range of spaces that meet users wherever they’re at in their growth cycle.”

Andy Gloor, Sterling Bay’s CEO